Navigation Links
Atlas Genetics Raises $35m in Series D Fundraising
Date:1/23/2017

BATH, England, January 23, 2017 /PRNewswire/ --

Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces completion of its Series D financing, raising $35 million from a syndicate including all Series C Investors and one new investor, Wondfo Biotech.

Development of the Atlas Genetics io® system has been completed with the successful CE marking of the Chlamydia trachomatis (CT) test announced in February 2016.  This new Series D equity issue will finance the clinical trials and commercial launch of a second test, for detection of both Chlamydia and Gonorrhoea, planned for regulatory approvals in the US around the end of 2017, as well as further development of additional diagnostics menu. The financing also provides funding to expand cartridge manufacturing capacity at Bespak, Atlas Genetics' cartridge manufacturing partner.

The io® system is a highly novel molecular diagnostic platform for the ultra-rapid diagnosis of a broad range of infectious diseases. The system offers a sample-to-answer time of under 30 minutes making it possible to carry out infectious disease tests in primary care clinics and physicians' offices that are as accurate as those carried out in hospital laboratories.  It is based on a patent-protected electrochemical sensor technology that combines speed, accuracy and low manufacturing costs. The fully integrated cartridge contains all reagents and is designed to receive an unprocessed clinical specimen. Each cartridge can detect up to 24 different genetic targets from a single patient sample.

Wondfo Biotech, the new investor, is a well-established Chinese in vitro diagnostic company, with over 1,000 employees based in Guangzhou, Guangdong Province, that develops and manufactures a broad range of diagnostic assays including several POC tests.  Existing investors include Novartis Venture Funds, Consort Medical plc, Johnson & Johnson Innovation - JJDC, Inc., LSP, BB Biotech Ventures, RMI Partners and Technology Venture Partners.  This new financing follows on from the previously announced Series C fundraising of $20 million in January 2015.

Dr John Clarkson, Chief Executive Officer of Atlas Genetics, commented:

"We have continued to make excellent progress and are delighted to have raised significant funds to allow us to complete clinical trials, registration and launch in Europe and the US of our flagship product, a combined CT/NG (Chlamydia / Gonorrhoea) test, as well as to further our menu development. Our system will enable physicians to test and treat patients immediately for what can be distressing conditions.  Immediate treatment enables better antibiotic stewardship and prevents onward transmission, which will help to reduce the associated financial burdens that these infections place on our healthcare systems.  We believe that Atlas Genetics is poised to become a world leader in POC molecular diagnostics and we plan to roll-out new assays in a range of clinical areas over the next two years and beyond."

NOTES TO EDITORS 

Atlas Genetics (http://www.atlasgenetics.com)

Atlas Genetics develops ultra-rapid POC diagnostic tests for infectious diseases. The Atlas Genetics' io® system uses patented technology based on the use of a novel electrochemical sensor that combines speed, accuracy and multiplex detection capability with low manufacturing costs.  The company has its head office and laboratory facilities near Bath in the UK with a commercial office in Boston, MA.

Wondfo Biotech (http://www.wondfo.com.cn

Wondfo Biotech Co., Ltd was founded in 1992 as a research based company on the campus of South China University of Technology in Guangzhou, Guangdong Province. The corporation quickly grew beyond research purposes towards custom manufacturing of quality medical products and biochemical reagents. Wondfo has obtained ISO 9001 certificate, GMP approval, FDA approval and CE Mark and has pioneered new and advanced engineering techniques in diagnostic manufacturing.  The Company has a worldwide network of offices and distributors employing over 1,000 people in state of the art facilities incorporating laboratory, office and manufacturing space, including a facility in San Diego, USA. Wondfo has a market capitalisation of around $US1.5 Billion and consensus estimates for revenue in 2016 of around $US 75

Million.

Contact details:

Atlas Genetics Ltd:
John Clarkson
Tel: +44(0)1225-717930

FTI Consulting:
Mo Noonan / Ben Atwell / Matthew Moss
Tel: +44(0)20-3727-1000



'/>"/>
SOURCE Atlas Genetics Ltd.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Atlas Genetics Gains CE Approval for First Product
2. First US Commercial Appointment: Atlas Genetics Appoints Keith Stauffer as VP Sales & Marketing
3. OfferBoard Securities Announces Series B Financing for Atlas Spine and its Novel Array of Spine Solutions
4. Atlas Venture Names Jason Rhodes, Veteran Investor and President and CFO of Epizyme, As Partner on Life Sciences Investing Team
5. Texas Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry
6. Atlas Appoints David Whitaker as Operations Director
7. Roka Bioscience Atlas System For Food Pathogen Detection Integrated At Department of Defense Food Analysis and Diagnostic Laboratory
8. Proteome atlas for the tuberculosis pathogen
9. Ovation Fertility™ Genetics Formed to Provide Accurate and Reliable PGS for IVF Clinics
10. Regeneron Genetics Center and Geisinger Study Finds Life-Threatening Genetic Disorder is Substantially Underdiagnosed
11. What to Look for in These Biotech Stocks? Threshold Pharma, Seattle Genetics, Chiasma, and Ophthotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 26, 2017 , ... WonderWorks, Myrtle Beach’s science focused amusement ... of deep space exploration and inspire space enthusiasts. The exhibit features interactive exhibits ... guest appearance by former Shuttle Astronaut Don Thomas. , The intergalactic weekend kicks ...
(Date:4/26/2017)... ... April 26, 2017 , ... As the call ... healthcare industry stakeholders, the discussion surrounding the topic will continue at WEDI 2017- ... in Los Angeles, Calif. Hosted by the Workgroup for Electronic Data Interchange (WEDI), ...
(Date:4/25/2017)... R.I. , April 25, 2017 ... Inc. ("EpiVax") has licensed its novel immune-modulating technology to ... autoimmune disease and allergy. Tregitopes, pronounced ... in human immunoglobulin by EpiVax CEO Annie ... Similar to intravenous immunoglobulin G, an autoimmune disease ...
(Date:4/24/2017)... , April 24, 2017  Dante Labs announced today the ... EUR 850 (ca. $900). While American individuals have been able ... time Europeans can access WGS below EUR 1,000. ... to leveraging genetic information to make informed decisions about disease ... ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):